In this inmunoespec\u00edficamente provide, Antibodies that bind to an Antigen of Human kit that includes the type extraceluar Fourth IG domains and \/ or Fifth (i.e., domains and \/ or D4, D5) polynucleotides comprising nucleotide sequences encoding these Antibodies and VEC Expression and activity of host cells to produce such Antibodies.The Antibodies can inhibit the activity of Kit, as the ligand induced phosphorylation of the receptor.Also provided are Pharmaceutical compositions and Kits comprising Antibodies that bind to a specific antigen Kit, as well as methods to Treat or manage a disorder or disease mediated by Kit and Methods for Diagnosing a disorder or disease mediated by Kit using The Antibodies described in the present.Claim 1: an Antibody that binds to a region inmunoespec\u00edficamente D4 \/ D5 Kit human (SEQ ID no. 15), characterized in that it comprises: (i) a light chain variable region (VL) comprising a VL CDR1, CDR2 and CDr3 VL VL has the Amino Acid Sequence SEQ ID no. SEQ ID no. 20, 21 and SEQ ID no. 22Respectively and (ii) a variable region of heavy chain (VH) comprising a VH CDR1, CDR2 and CDr3 VH VH has the Amino Acid Sequence SEQ ID no. 23, SEQ ID no. SEQ ID no. 24 and 25, respectively.En la presente se proveen, anticuerpos que se unen inmunoespecíficamente con un antígeno de KIT humano que comprende los dominios tipo Ig extraceluar cuarto y/o quinto (es decir, dominios D4 y/o D5), polinucleótidos que comprenden secuencias de nucleótidos que codifican dichos anticuerpos y vectores de expresión y células huésped para producir tales anticuerpos. Los anticuerpos pueden inhibir la actividad de KIT, como la fosforilación del receptor inducida por ligando. También se proveen Kits y composiciones farmacéuticas que comprenden anticuerpos que se unen específicamente a un antígeno de KIT, así como métodos para tratar o controlar un trastorno o enfermedad mediado por KIT y métodos para diagnosticar un trastorno o enfermedad mediados por KIT usando l
